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Hemodiafiltration (HDF) is used sporadically for renal
replacement therapy in Europe but not in the US.
Characteristics and outcomes were compared for patients
receiving HDF versus hemodialysis (HD) in five European
countries in the Dialysis Outcomes and Practice Patterns
Study. The study followed 2165 patients from 1998 to 2001,
stratified into four groups: low- and high-flux HD, and
low- and high-efficiency HDF. Patient characteristics
including age, sex, 14 comorbid conditions, and time on
dialysis were compared between each group using
multivariate logistic regression. Cox proportional hazards
regression assessed adjusted differences in mortality risk.
Prevalence of HDF ranged from 1.8% in Spain to 20.1% in
Italy. Compared to low-flux HD, patients receiving
low-efficiency HDF had significantly longer average duration
of end-stage renal disease (7.0 versus 4.7 years), more history
of cancer (15.4 versus 8.7%), and lower phosphorus (5.3
versus 5.6 mg/dl); patients receiving high-efficiency HDF had
significantly more lung disease (15.5 versus 10.2%) and
received a higher single-pool Kt/V (1.44 versus 1.35).
High-efficiency HDF patients had lower crude mortality rates
than low-flux HD patients. After adjustment, high-efficiency
HDF patients had a significant 35% lower mortality risk than
those receiving low-flux HD (relative risk¼ 0.65, P¼ 0.01).
These observational results suggest that HDF may improve
patient survival independently of its higher dialysis dose.
Owing to possible selection bias, the potential benefits of
HDF must be tested by controlled clinical trials before
recommendations can be made for clinical practice.
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Despite ongoing technical improvements in both dialysis and
overall patient care, the annual mortality rate of patients with
end-stage renal disease (ESRD) managed with thrice-weekly
hemodialysis (HD) remains high (10–22%).1,2 Factors
affecting HD patient mortality include advanced age and
comorbid conditions at the start of dialysis;3 the efficacy and
quality of renal replacement therapy;4 and practice pattern
variation from region to region.5
The clinical condition of patients starting dialysis has been
deteriorating over the last decade, as the advanced age and the
increased prevalence of comorbid conditions (e.g. diabetes,
cardiovascular disease, and malnutrition) among incident ESRD
patients expose them to a higher mortality risk than in the
past.6 However, HD techniques have clearly improved over the
last few years. Advanced technical options – such as bicarbonate
buffer, ultrafiltration control, sodium and ultrafiltration profil-
ing, and blood volume monitoring – have become routine
procedures for reducing intradialytic morbidity, which is
particularly important for patients who are older or sicker.
The performance and quality of HD have also improved in
relation to efficacy (through enhanced clearances for small
and large solutes) and greater biocompatibility (through use
of biocompatible membranes and higher quality dialysate).7–10
More holistic ESRD patient care has seen greater research and
clinical emphasis on the correction of anemia by erythropoie-
tic agents, the control of hypertension by adequate ultrafiltra-
tion and antihypertensive drugs, and control of potentially
atherogenic dyslipidemia by lipid-lowering agents.11,12
The recently completed hemodialysis (HEMO) Study was
a randomized, controlled clinical trial that tested the role
of high-flux membranes and high-efficiency dialysis on the
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morbidity and mortality of HD patients treated three times
per week. The results showed no major overall beneficial
effects of an increase in dialysis dose above the currently
recommended standard and no improvement in mortality
with use of high-flux membranes in 1846 patients followed
up to 6.5 years.13 Although the effect of dose (small solute
clearance) was definitive, convective-based therapies (hemo-
filtration, hemodiafiltration (HDF)) were not tested, so the
role of large solute removal and its effect on patient outcomes
requires further testing.14
In its search for ways to improve dialysis patient
outcomes, the nephrology community has suggested that
convective-based therapies represent promising modalities.15
In this context, HDF is appealing. By combining ultra-
filtration (convective clearances for removing larger solutes)
with diffusion (for removal of small solutes), HDF offers
an effective dialysis modality expanding spectrum of uremic
toxins to middle-sized and large molecular weight solutes.16,17
In addition, the ultrapure dialysis fluid and sterile substitution
fluid used for infusion during HDF, combined with high-flux
synthetic membranes, results in optimized biocompatibility
of the extracorporeal circuit.
Several limited clinical studies have suggested that HDF is
associated with superior tolerance and efficacy compared to
conventional and high-flux HD. Our study aims to compare
the mortality rates of patients receiving HDF to those of
patients receiving HD in a large cohort of HD patients
followed prospectively in the Dialysis Outcomes and Practice
Patterns Study (DOPPS).18–22 To minimize the confounding
by regional variations in other practice patterns, we selected
and analyzed data only from patients in the European cohort
of the DOPPS.
RESULTS
Study population
The distribution of dialysis modality for patients at baseline
is presented in Table 1. Patients receiving HDF represented
11.7% and those receiving HD represented 88.3%. Among all
patients in the study, 7.2% received low-efficiency HDF, 4.5%
received high-efficiency HDF, 63.1% received low-flux HD,
and 25.2% received high-flux HD.
Patient characteristics, treatment regimens, and intermedi-
ate outcomes
Patient characteristics by treatment modalities at baseline are
presented in Table 2. As shown in Table 2, patients treated by
HDF versus HD tended to be slightly older, have higher body
weight, and have longer average time on renal replacement
therapy. In addition, patients receiving HDF were more likely
to have had lung disease (significantly for high-efficiency
HDF versus low-flux HD) and cancer (significantly for low-
efficiency HDF versus low-flux HD). It appears that patients
were preferentially selected for HDF because of their higher
weight and their poor clinical conditions.
Indicators used to evaluate dialysis adequacy in the four
dialysis modalities are also presented in Table 2. As shown in
Table 2, dialysis dose (Kt/V) was the only treatment
parameter that differed significantly among dialysis mod-
alities. The highest Kt/V values were achieved among patients
receiving low- and high-efficiency HDF (averages of 1.37
and 1.44), comparing favorably to the Kt/V values achieved
by patients receiving HD (averages of 1.35 for low-flux and
1.33 for high-flux). Most nutritional markers (albumin,
cholesterol, triglycerides) of HDF patients did not differ
significantly from those of low-flux HD patients. The quality
of life scores of HDF patients (both mental and physical
component summaries) did not differ significantly from
those of low-flux HD patients. Similarly, no difference by
modality was found for predialysis blood pressure (systolic
or diastolic), acid–base status, or serum levels of potassium
or calcium. As shown in Table 2, markers of dialysis efficacy
for HDF and HD patients were very similar and within
acceptable limits. Such results suggest that most of the ESRD
patients in the study received adequate renal replacement
therapy.
Adjustments for intermediate outcomes included age, sex,
country, time on dialysis, 14 comorbid conditions, catheter
use, and weight, as listed in Table 3. Table 3 shows that HDF
patients received a higher dialysis dose (þ 0.06 Kt/V higher)
than low- and high-flux HD patients. Additionally, a trend was
observed in HDF patients for higher hemoglobin concentration
(þ 0.39 g/dl for low-efficiency HDF (P¼ 0.01); þ 0.34 g/dl for
high-efficiency HDF (NS)).
Indicators of inflammation are presented in Table 4. As
C-reactive protein measurements were not recorded in
DOPPS I, three alternative markers of inflammation were
used to assess the consequences of large volume of intra-
venous replacement fluid during HDF treatment; the markers
used were albumin, negative protein of the acute phase;
ferritin, positive protein of the acute phase; and transferrin
saturation. As shown in Table 4, patients receiving HDF
tended to have a greater likelihood of having albumin
concentration 44.0 g/dl and a lower likelihood of having
ferritin concentration 4800 ng/dl, compared with low-flux
HD patients. The finding on ferritin persisted after adjusting
for transferrin saturation.
Table 1 | Distribution of dialysis modality for prevalent
cross-section of patients at baseline
Country n
Patients (%)
Low-efficiency
HDFa
High-efficiency
HDFa
Low-flux
HD
High-flux
HD
France 460 5.4 8.9 45.9 39.8
Germany 440 11.1 4.8 50.5 33.6
Italy 443 14.7 5.4 74.9 5.0
Spain 383 1.8 0.0 61.4 36.8
UK 439 2.3 2.5 83.4 11.8
All 2165 7.2 4.5 63.1 25.2
aLow-efficiency HDF includes replacements of 5–14.9 l, while high-efficiency HDF
includes replacement of 15–24.9 l.
HD, hemodialysis; HDF, hemodiafiltration.
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Crude mortality
Over the period of observation (1998–2001), the crude
mortality in this cohort was 35 deaths/278 patient years in
the low-flux HD group (12.8 deaths per 100 patient years),
152 deaths among the 1194 patient years in the high-flux HD
group (12.7 deaths per 100 patient years). The high-efficiency
HDF group had 15 deaths in 169 patient years (8.9 deaths
per 100 patient years), and the low-efficiency HDF group had
35 deaths in 278 patient years (12.6 deaths per 100 patient
years).
Relative risk of mortality
The relative risk of mortality after adjustments for all
variables, including dialysis dose (Kt/V), is presented in
Figure 1. The relative risk of mortality was significantly reduc-
ed by 35% for patients receiving high-efficiency HDF com-
pared to low-flux HD (relative risk (RR)¼ 0.65, P¼ 0.01).
Patients receiving low-efficiency HDF exhibited a nonsigni-
ficant 7% reduction in mortality risk compared to those
receiving low-flux HD (RR¼ 0.93, P¼ 0.68). Since the results
for low- and high-flux in the present study were very similar,
the HDF results can be compared to all HD combined. In
this comparison, the RR for low-efficiency HDF was 0.92
(P¼ 0.066) and for high-efficiency HDF again significantly
lower (RR¼ 0.64, P¼ 0.005). An additional analysis that only
adjusted for demographic and comorbid conditions (i.e. not
adjusting for the potential benefits of HDF, such as higher
Kt/V) yielded similar results: the relative risk of mortality was
significantly reduced by 35% for patients receiving high-
efficiency HDF (RR¼ 0.65, P¼ 0.008) and nonsignificantly
reduced by 13% for patients receiving low-efficiency HDF
(RR¼ 0.87, P¼ 0.46) (data not shown).
Table 2 | Crude patient characteristics by dialysis type (mean or %)
Measure Low-efficiency HDFa (n=156) High-efficiency HDFa (n=97) Low-flux HD (n=1366) High-flux HD (n=546)
Characteristic
Age (years) 61.8 63.5 60.4 58.5*
Male (%) 57.1 66.0 55.7 58.0
Time on dialysis (years) 7.0* 5.2 4.7 5.5*
Comorbid conditions (%)
CAD 35.3 28.8 28.5 30.6
CHF 23.7 25.8 25.9 25.5
Other cardiac disease 51.9 40.2 35.2 36.9
Hypertension 71.1 76.3 71.6 76.0
Cerebrovascular disease 15.4 11.3 13.8 12.5
PVD 25.0 25.8 21.8 22.4
Diabetes 21.8 26.8 18.7 21.3
Lung disease 10.9 15.5* 10.2 11.7
Cancer (excluding skin) 15.4* 8.2 8.7 8.8
HIV/AIDS 0.0 0.0 0.0 0.4
GI bleed 2.6 6.2 4.6 7.2*
Neurological disorder 5.8 4.1 5.7 6.6
Psychiatric disease 28.8 27.8 23.6 24.6
Recurrent cellulitis/gangrene 5.1 7.2 6.7 6.2
Catheter use (%) 3.4 2.2 11.7 5.9*
Weight (kg) 68.6* 70.1* 65.0 67.1*
Hemoglobin (g/dl) 11.0* 10.6 10.7 10.6
Epo dose (U/week)b 6428 5334 6386 7083*
Albumin (g/dl) 3.95 3.83 3.91 3.96
nPCR (g/kg/day) 1.13* 1.08 1.09 1.10
Cholesterol (mg/dl) 196 193 191 188*
Triglycerides (mg/dl) 173 176 165 160
Dialysis dose (spKt/V) 1.37 1.44* 1.35 1.33
Treatment time (min) 234* 221* 233 233*
QoL: MCS 43.7 43.2 42.9 43.1
QoL: PCS 34.2 35.5 35.2 36.4
Predialysis systolic BP (mm Hg) 142 145 145 144
Predialysis diastolic BP (mm Hg) 77 77 79 78
Potassium (mEq/l) 5.5 5.3 5.4 5.3
Phosphorus (mg/dl) 5.3* 5.6 5.6 5.9
Calcium (mg/dl) 9.7* 9.4 9.6 9.4
Bicarbonate (mEq/l) 22.1 21.6 22.3 22.4
*Po0.05 versus low-flux HD, adjusts for country and accounts for facility clustering.
aLow-efficiency HDF includes replacements of 5–14.9 l, while high-efficiency HDF includes replacement of 15–24.9 l.
bAmong patients on Epo.
BP, blood pressure; CAD; CHF; Epo, erythropoietin; GI; HD, hemodialysis; HDF, hemodiafiltration; HIV/AIDS, human immunodeficiency virus/acquired immuno deficinecy
synodrome; nPCR, normalized protein catabolic rate; PCS; PVD; QoL, quality of life.
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DISCUSSION
This study suggests that high-efficiency HDF has an
important positive impact on survival compared to patients
treated by HD. This finding supports the hypothesis that
convective clearances enhancing the removal of large
molecular solutes have a strong impact on survival of dialysis
patients.23–25 There are several potential explanations for
this effect. The benefit may be partly explained by the small
solute dialysis dose (Kt/V urea) delivered by HDF, which is
higher than that delivered by HD. We found patients
receiving HDF to have Kt/V of 1.37 (low efficiency) and
1.44 (high efficiency) versus 1.35 (low-flux HD) and 1.33
(high-flux HD), a difference that confirms the findings of
previous studies.26,27 However, when the adjustment for Kt/V
urea was removed, the results were essentially unchanged.
Another potential explanation is the significant increase in
larger solute removal achieved by convective clearance.28 This
latter explanation is more attractive because the beneficial
effects of HDF in terms of reducing mortality risk still
persisted after statistical adjustment for dialysis dose (Kt/V).
Moreover, relative reduction in mortality risk may be propor-
tional to the intensity of the convective clearance, which itself
is linearly related to the amount of fluid exchanged during
the sessions. As indicated in Figure 1, the HDF group
receiving the higher fluid volume exchange (15–24.9 l per
session) had a significantly and substantially lowered risk of
death (RR¼ 0.65, P¼ 0.01) .
To our knowledge, this is the first study in a large cohort
of patients suggesting that high-efficiency HDF is associated
with reduced mortality risk compared to both low- and high-
flux HD. This potentially beneficial life-saving effect of HDF
in dialysis patients still persists after correcting for demo-
graphic factors, comorbid conditions, and several potentially
confounding therapy-related factors, including previous time
spent on dialysis and dialysis dose. It should be noted that
HDF patients had more comorbid conditions than HD
patients, particularly cardiovascular diseases, underlining the
fact this population may have been negatively selected to be
treated by HDF.
The superiority of HDF compared to conventional (low-
or high flux) HD in potentially improving patient longevity
is a quite recent finding.29 This original observation deserves
further study and comment. The exact mechanism by which
HDF might reduce mortality when compared to HD is not
entirely apparent and is beyond the scope of this study.
Table 3 | Adjusteda intermediate outcomes, by dialysis type: direction and extent of difference from low-flux HD group
(P-value)
Outcome Low-efficiency HDFb High-efficiency HDFb High-flux HD
Hemoglobin (g/dl) +0.39 (0.01) +0.34 (0.13) +0.13 (0.12)
Epo dose (U/week)c 13 (0.98) 551 (0.46) +541 (0.07)
Epo dose/Hgb (U/week)c 21 (0.70) 58 (0.47) +49 (0.13)
Albumin (g/dl) +0.03 (0.39) +0.05 (0.40) +0.03 (0.16)
nPCR (g/kg/day) +0.02 (0.20) 0.03 (0.22) +0.00 (0.81)
Cholesterol (mg/dl) +0 (0.86) +0 (0.93) 4 (0.01)
Triglycerides (mg/dl) +4 (0.35) +5 (0.42) 4 (0.12)
Dialysis dose (spKt/V) +0.01 (0.57) +0.06 (0.03) 0.02 (0.15)
QoL: MCS +1.6 (0.06) 0.0 (0.99) 0.1 (0.89)
QoL: PCS 0.3 (0.69) +0.4 (0.66) +0.3 (0.45)
aAdjusted for age, sex, country, time on dialysis, 14 comorbid conditions, catheter use, and weight.
bLow-efficiency HDF includes replacements of 5–14.9 l, while high-efficiency HDF includes replacement of 15–24.9 l.
cAmong patients on Epo.
Epo, erythropoietin; HD, hemodialysis; HDF, hemodiafiltration; MCS; nPCR, normalized protein catabolic rate; PCS; QoL, quality of life.
Table 4 | Adjusted intermediate outcomes for surrogate inflammation markers, by dialysis modality
OR (P-value)
Outcomea Low-efficiency HDFa High-efficiency HDFa High-flux HD Low-flux HD
Albumin44.0 g/dl 1.44 (0.07) 1.27 (0.58) 1.26 (0.22) 1.00 (ref)
Ferritin4800 ng/dl 0.59 (0.07) 0.92 (0.86) 0.96 (0.81) 1.00 (ref)
Ferritin4800 ng/dl, adjusted for TSAT 0.62 (0.09) 0.99 (0.99) 0.97 (0.88) 1.00 (ref)
aAdjusted for age, sex, country, time on dialysis, 14 comorbid conditions, catheter use, and weight. Accounts for facility clustering.
HD, hemodialysis; HDF, hemodiafiltration; OR, odds ratio; TSAT.
1.00 1.03 0.93
0.65
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Low-flux HD High-flux HD Low-efficiency
HDF
High-efficiency
HDF
R
el
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k
Ref P=0.83 P=0.68 P=0.01
Figure 1 | Relative risk of mortality by dialysis type. (Adjusted for
age, sex, time on dialysis, 14 summary comorbid conditions, weight,
catheter use, hemoglobin, albumin, normalized protein catabolic
rate, cholesterol, triglycerides, Kt/V, erythropoietin, MCS, and PCS.)
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However, several explanations may be proposed to support
this finding. Schematically, HDF’s beneficial effects fall
into three categories. First, as described above, HDF enhances
solute removal of small solutes (urea and creatinine),
expands the spectrum of solute removal to include middle-
sized and large molecular weight substances.30 Second,
on-line HDF enhances intradialytic hemodynamic stability,
which facilitates treatment of elderly and high-risk patients.
Third, HDF may improve the biocompatibility of the
dialysis system, reducing bioactivation and its subsequent
inflammation.31
The superiority of on-line HDF to HD has been suggested
by the results of several studies.32–34 Solute removal capacity
of uremic toxins is enhanced by high-efficiency on-line
HDF.35 Most clinical studies agree that on-line HDF permits
a similar reduction rate of small solutes per session as that
of HD: 70–80% for urea (60 daltons (da)).36 Using B2M as a
solute marker of larger uremic toxins, it has been shown in a
controlled study that the reduction ratio of B2M per session
was 20–30% higher with on-line HDF than with high-flux
HD (72.7 versus 49.7%), and that regular use of on-line HDF
significantly reduces circulating levels of predialysis B2M
(median value 20 mg/l).20 It has also been shown that HDF
can clear larger solutes such as myoglobin (16 kDa) and
retinol-binding protein (25 kDa).21,37 The capacity to remove
middle-sized peptide substances is positively correlated to the
convective clearance and the amount of fluid exchanged per
session, and it is the enhanced convective clearance achieved
by HDF that is the primary mechanism for removing larger
uremic solutes.38,39 A new aim in dialysis adequacy is to
prevent B2M-amyloid occurrence and possibly to reduce
patient mortality by using highly permeable and biocompa-
tible membranes.40 Very recently, it has been shown that
some protein-bound solutes (p-cresol) may be more
efficiently removed by high-efficiency HDF than by high-
flux HD.41 It has also been shown that on-line HDF reduces
the circulating levels of advanced glycation end products that
are putatively implied in the dialysis-related complications of
long-term dialysis patients.42
A number of studies in the late 1970s and early 1980s
demonstrated superior hemodynamic stability with HDF as
compared with HD, although these earlier studies involved
comparisons with those receiving acetate-buffered dialysate.
Although this issue has not been entirely resolved, at least
some prospective controlled reports and more recent obser-
vational reports also suggest an advantage in comparison to
controls treated with bicarbonate-buffered dialysate.33,43,44
This unique property of HDF and other convective therapies
makes HDF quite useful in treating patients who are elderly,
heart-compromised, or prone to hypotension. The precise
mechanisms by which HDF maintains the arterial pressure
during dialysis sessions are not completely understood.
However, several studies tend to favor the hypothesis that
hemodynamic stability depends on the increase of the
peripheral vascular tone (arterial and venous) and the
vascular refilling rate due to the neutral thermal balance.45,46
Several other factors may contribute to this hemodynamic
adaptation during HDF, although they remain largely
speculative: high sodium concentration of the substitution
dialysis fluid, release of vasoconstrictor mediators (e.g.
endothelin, renin, angiotensin), clearance of vasodilator
mediators, and improvement of sympathetic activity facili-
tating adaptation of heart rate and vascular resistance.47
HDF combines the use of high-flux synthetic membrane
with low bioreactive profile and the use of ultrapure
dialysis fluid. This combination is recognized as beneficial
in reducing the bioactivation (circulating cells and protein
systems) induced by blood–hemodialyzer interaction.
Longitudinal studies have also shown that the release of
proinflammatory mediators (interleukin-1, interleukin-6,
tumor necrosis factor) resulting from the patient–hemodia-
lyzer interaction is significantly reduced for patients receiving
on-line HDF.48 Using well accepted markers of inflammation
(albumin, ferritin, and transferrin saturation), our study is
in agreement with these findings, showing that despite the
administration of large volumes of intravenous replacement
fluid, HDF is associated with a lower microinflammatory
profile than HD.49,50 This effect is of particular importance,
as it prevents the induction of microinflammation reaction in
HD patients, a state that favors long-term dialysis complica-
tions (such as B2M-amyloidosis and atherosclerosis).51,52
In addition to its beneficial effects on ESRD patient
mortality, on-line HDF may have been associated with a
positive effect on anemia correction. This statistically non-
significant finding agrees with prior findings that switching
from HD to HDF was associated with a higher hemoglobin
level and a reduced weekly consumption of erythropoietin.53
Since this study also agrees with findings from previous
comparative HD/HDF studies, further randomized con-
trolled studies should be considered.54,55 However, one can
speculate that HDF, by enhancing the removal of larger
uremic toxins and by reducing the inflammation state of
patients, may remove some specific receptor antagonists
of erythropoietin and thereby increase the sensitivity of
erythroblasts to the drug.
Conclusion
This is the first large observational cohort study with robust
adjustments for demographic and comorbid confounding
factors to show an association with lower mortality risk for
HDF. The modality’s beneficial effects on patient outcomes
are not related to dialysis dose for small molecules (Kt/Vurea),
but may be related to factors particular to HDF, which
combines enhanced removal of larger molecular weight
substances with an improved biocompatible system.
MATERIALS AND METHODS
Data sources
This analysis used a sample of 2165 European HD patients from the
DOPPS I, an international, prospective, observational study
involving adult HD patients randomly selected from 308 represen-
tative dialysis facilities. A total of 101 European facilities (21 in
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Germany and 20 each in France, Italy, Spain, and the UK) enrolled
patients. In each facility, an algorithm was used to create a sample of
20–40 patients, depending upon facility size. The DOPPS I sampling
plan and study methods have been described elsewhere.56 Consent
to collect anonymous patient information was obtained as needed
from the local or national Ethics Committee or Institutional Review
Board. Data collection began in 1998 and was gathered at 4-month
follow-up intervals through early 2001.
Classification of HD and HDF modalities
HDF operating parameters were reported for each patient by the
nurse coordinator at each center; HDF was defined as the patient
‘routinely receiving replacement fluid intravenously as part of the
treatment.’ Data were also captured regarding how much fluid was
replaced and this was used to further refine treatment definitions.
Patients replacing 15–24.9 l of fluid per treatment were classified as
receiving high-efficiency HDF, while patients replacing 5–14.9 l of
fluid per treatment were classified as receiving low-efficiency HDF.
HD patients not receiving fluid replacement were classified by the
type of dialyzer used (high-flux: KUF 420 ml/h/mm Hg versus
low-flux: KUFp20 ml/h/mm Hg) independent of the membrane
type. KUF, or ultrafiltration coefficient, is a measure of membrane
permeability. A total of 253 patients were classified as receiving
either low- or high-efficiency HDF.
Statistical methods
The distribution of dialysis type was examined by country in a
prevalent cross-section of patients (n¼ 2165). The same sample was
used to compare patient demographics (age, sex, time on dialysis),
baseline comorbid conditions (listed in Table 2), weight, catheter
use for vascular access, hemoglobin, serum albumin, normalized
protein catabolic rate, cholesterol, triglycerides, dialysis dose (Kt/V),
erythropoietin use and dosage, two summary scales from the SF-36
quality of life questionnaire (MCS and PCS),57,58 and HDF status.
Linear mixed models and logistic regression models were used to
compare both unadjusted and adjusted means and proportions,
using the low-flux HD patients as the reference group. All models
adjusted for country and accounted for facility clustering. Adjusted
models took into account the patient characteristics described
above.
Crude mortality rates were calculated for each treatment group
and expressed as deaths per 100 patient years. Cox proportional
hazards regression models were employed to examine the relation-
ship between mortality and dialysis type, with the adjustments
described above. Cox models were stratified by country of residence
and a robust variance estimate (the sandwich estimator) was used to
account for clustering at the facility level.59
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